Global Harmonization Working Party
GHWP Towards Medical Device Harmonization



Medical Algorithm
Amplify the early-stage signs of HCC

Asmaa Awad- Global Regulatory Policy EEMEA

Roche Diagnostics

27th GHWP Annual Meeting and 27th GHWP TC Meeting, 27th - 30th Nov 2023
Shanghai International Convention Center

Global Harmonization Working Party
GHWP Towards Medical Device Harmonization

Liver cancer (HCC) is a global disease burden

If diagnosed early, the 5 year survival rate for HC increases significantly to 40-70%[1,2]

Occurring almost exclusively in patients with chronic liver disease[3], HCC is most common form of liver cancer, accounting for nearly 90% of cases, and is also the third leading cause of cancer death.[1,4,5]

We need to diagnose HCC earlier. In fact, in high risk groups, biannual screening has decreased HCC mortality by 37%.[6]



1. El-Serag HB et al. Surveillance for hepatocellular carcinoma: in whom and how? Ther Adv Gastroenterol 2011; 4: 5–10.
2. Kao, Wei-Yu et al. "Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients." Medicine vol. 94,43 (2015): e1929.
3. Bartosch B. Hepatitis B and C Viruses and Hepatocellular Carcinoma. Viruses 2010;2:1504.
4. Llovet JM et al. Hepatocellular carcinoma. Nat Rev Dis Prim 2016;14:2:16018.
5. Ferlay J, et al. (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed August 2021.
6. Zhang BH et al. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130: 417-22.

Global Harmonization Working Party
GHWP
Towards Medical Device Harmonization

How do we create value in a fragmented landscape?



Algorithm Suite



Global Harmonization Working Party
GHWP Towards Medical Device Harmonization

Medical Algorithm

1st multivariate surveillance HCC test



- Both biomarkers on a **fully automated IVD** platform[1]
- **Clinical performance** demonstrated in early evaluation in publication[2]
- **Superior performance** to AFP alone[2]

PRECAUTION: Assay results from other manufacturers have not been validated for the use of the Elecsys® GAAD test. The Elecsys® GAAD test should not be used without an independent clinical/radiological evaluation for the diagnosis of Hepatocellular Carcinoma (HCC). For each Elecsys® GAAD determination the measurement of the Elecsys® AFP and Elecsys® PIVKA-II assays must be determined from the same sample and measurement performed on the same analyzer type (either on **cobas e** 402, **cobas e** 411, **cobas e** 601, **cobas e** 602 or **cobas e** 801 analyzers)

1 Elecys® GAAD Method Sheet
2 Chan et al. (2022) Poster 3345 Presented at EASL ILC 2022, 22–26 June, 2022. International Liver Congress

Seamless workflow integration

GAAD integrates directly into the current workflow with navify Algorithm Suite



Global Harmonization Working Party
GHWP Towards Medical Device Harmonization

Medical algorithms support clinical decision- making across the patient journey



1. Muhiya Addin, R. et al. 'The Impact of Clinical Decision Support Systems (CDSS) on Physicians: A Scoping Review'. 2020 June 26;272:470-473; https://pubmed.ncbi.nlm.nih.gov/32604704/
2. Sutton, R.T. et al. 'An overview of clinical decision support systems: benefits, risks, and strategies for success'. npj Digital Medicine (2020) 3:17; https://www.nature.com/articles/s41746-020-0221-y
3. Basile, J. 'Clinical Inertia and Blood Pressure Goal Attainment'. The Journal of Clinical Hypertension. 2009. SUPPL. 1 VOL. 11 NO. 12; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673201/3

Global Harmonization Working Party
GHWP Towards Medical Device Harmonization

Asmaa Awad
asmaa.awad@roche.com